Hugo Cheinquer

7.6k total citations · 1 hit paper
75 papers, 2.2k citations indexed

About

Hugo Cheinquer is a scholar working on Hepatology, Epidemiology and Rheumatology. According to data from OpenAlex, Hugo Cheinquer has authored 75 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Hepatology, 65 papers in Epidemiology and 8 papers in Rheumatology. Recurrent topics in Hugo Cheinquer's work include Hepatitis C virus research (65 papers), Liver Disease Diagnosis and Treatment (49 papers) and Hepatitis B Virus Studies (46 papers). Hugo Cheinquer is often cited by papers focused on Hepatitis C virus research (65 papers), Liver Disease Diagnosis and Treatment (49 papers) and Hepatitis B Virus Studies (46 papers). Hugo Cheinquer collaborates with scholars based in Brazil, United States and Argentina. Hugo Cheinquer's co-authors include Ching‐Lung Lai, Daniel Shouval, Ting‐Tsung Chang, Richard C. Zink, Richard B. Wilber, Zachary Goodman, Anna S. Lok, Deborah DeHertogh, Anne Cross and Richard J. Colonno and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Hugo Cheinquer

73 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B

2006 900 citations Ching‐Lung Lai, Daniel Shouval et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hugo Cheinquer Brazil	19	2.1k	2.0k	197	65	60	75	2.2k
Naoky Tsai United States	20	1.6k 0.8×	1.7k 0.8×	223 1.1×	33 0.5×	34 0.6×	55	1.8k
Selım Gürel Türkiye	20	2.8k 1.4×	2.8k 1.4×	227 1.2×	62 1.0×	38 0.6×	50	3.0k
Hillel Tobias United States	15	1.4k 0.7×	1.5k 0.7×	144 0.7×	76 1.2×	46 0.8×	22	1.7k
F Piccinino Italy	21	1.6k 0.8×	1.5k 0.8×	171 0.9×	77 1.2×	66 1.1×	84	1.8k
Pietro Filippini Italy	22	1.4k 0.7×	1.3k 0.6×	190 1.0×	41 0.6×	41 0.7×	54	1.5k
E. Schiff United States	15	1.0k 0.5×	1.0k 0.5×	163 0.8×	54 0.8×	51 0.8×	40	1.2k
Lisa M. Nyberg United States	16	1.5k 0.7×	1.4k 0.7×	241 1.2×	58 0.9×	143 2.4×	39	1.7k
Sarah Maylin France	23	1.9k 0.9×	2.0k 1.0×	321 1.6×	42 0.6×	101 1.7×	76	2.2k
Fredric Regenstein United States	16	1.1k 0.5×	1.0k 0.5×	117 0.6×	130 2.0×	61 1.0×	33	1.3k
G. Kitis Greece	17	2.4k 1.2×	2.5k 1.2×	364 1.8×	130 2.0×	41 0.7×	40	2.7k

Countries citing papers authored by Hugo Cheinquer

Since Specialization

Citations

This map shows the geographic impact of Hugo Cheinquer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hugo Cheinquer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hugo Cheinquer more than expected).

Fields of papers citing papers by Hugo Cheinquer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hugo Cheinquer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hugo Cheinquer. The network helps show where Hugo Cheinquer may publish in the future.

Co-authorship network of co-authors of Hugo Cheinquer

This figure shows the co-authorship network connecting the top 25 collaborators of Hugo Cheinquer. A scholar is included among the top collaborators of Hugo Cheinquer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hugo Cheinquer. Hugo Cheinquer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ferraz, Maria Lúcia Gomes, Hugo Cheinquer, Giovanni Faria Silva, et al.. (2022). National Brazilian survey on the outcomes of hepatitis c retreatment in patients non-responders to direct antiviral agents. The Brazilian Journal of Infectious Diseases. 26(4). 102388–102388. 3 indexed citations

Fabrizi, Fabrizio, Cristina Alonso, Margarita Anders, et al.. (2021). ‘Real-life’ experience with direct-acting antiviral agents for HCV after kidney transplant. Annals of Hepatology. 25. 100337–100337. 3 indexed citations

Araújo, Alexandre de, et al.. (2018). Bosentan Inducing Autoimmune Hepatitis in a Patient with Idiopathic Pulmonary Arterial Hypertension. Journal of Gastrointestinal and Liver Diseases. 27(1). 89–92. 3 indexed citations

Cheinquer, Hugo, et al.. (2017). Treatment of Chronic HCV Infection with the New Direct Acting Antivirals (DAA): First Report of a Real World Experience in Southern Brazil. Annals of Hepatology. 16(5). 727–733. 31 indexed citations

Cheinquer, Hugo, et al.. (2013). Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil. Cost Effectiveness and Resource Allocation. 11(1). 25–25. 11 indexed citations

Harrison, Stephen A., Mitchell L. Shiffman, И. Г. Бакулин, et al.. (2012). Intensified Peginterferon α-2a Dosing Increases Sustained Virologic Response Rates in Heavy, High Viral Load Hepatitis C Genotype 1 Patients With High Low-density Lipoprotein. Journal of Clinical Gastroenterology. 47(3). 271–279. 3 indexed citations

Marcellin, Patrick, Hugo Cheinquer, Manuela Curescu, et al.. (2012). High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology. 56(6). 2039–2050. 79 indexed citations

Cheinquer, Hugo, et al.. (2012). Effect of HFE gene polymorphism on sustained virological response in patients with chronic hepatitis C and elevated serum ferritin. Arquivos de Gastroenterologia. 49(1). 9–13. 4 indexed citations

Liaw, Yun‐Fan, M. Raptopoulou‐Gigi, Hugo Cheinquer, et al.. (2011). Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open-label study. Hepatology. 54(1). 91–100. 163 indexed citations

10.

Cheinquer, Hugo, et al.. (2010). Effect of sustained virologic response on the incidence of hepatocellular carcinoma in patients with HCV cirrhosis. The Brazilian Journal of Infectious Diseases. 14(5). 457–461. 12 indexed citations

11.

Reddy, K. Rajender, Mitchell L. Shiffman, M. Rodríguez‐Torres, et al.. (2010). Induction Pegylated Interferon Alfa-2a and High Dose Ribavirin Do Not Increase SVR in Heavy Patients With HCV Genotype 1 and High Viral Loads. Gastroenterology. 139(6). 1972–1983. 25 indexed citations

12.

Cheinquer, Hugo, et al.. (2009). Prevalence of hepatitis C virus infection in patients with COPD. Epidemiology and Infection. 138(2). 167–173. 21 indexed citations

13.

Chang, Ting‐Tsung, You‐Chen Chao, Kwang‐Hyub Han, et al.. (2009). Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside‐naïve HBeAg‐positive patients with chronic hepatitis B. Journal of Viral Hepatitis. 16(11). 784–789. 20 indexed citations

14.

Shouval, Daniel, Ching‐Lung Lai, Ting‐Tsung Chang, et al.. (2008). Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: The case for continuous antiviral therapy. Journal of Hepatology. 50(2). 289–295. 83 indexed citations

15.

Şentürk, Hakan, Yoav Lurie, Adrián Gadano, et al.. (2007). [517] ETV RE-TREATMENT OF NUCLEOSIDE-NAIVE HBeAg(−) PATIENTS. Journal of Hepatology. 46. S197–S197. 4 indexed citations

16.

Lai, Ching‐Lung, Daniel Shouval, Anna S. Lok, et al.. (2006). Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B. New England Journal of Medicine. 354(10). 1011–1020. 900 indexed citations breakdown →

17.

Sullivan, Sean D., Donald M. Jensen, David Bernstein, et al.. (2004). Cost-Effectiveness of Combination Peginterferon alpha-2a and Ribavirin Compared With Interferon alpha-2b and Ribavirin in Patients With Chronic Hepatitis C. The American Journal of Gastroenterology. 99(8). 1490–1496. 47 indexed citations

18.

Cheinquer, Hugo, et al.. (2004). Intranasal cocaine use does not appear to be an independent risk factor for HCV infection. Addiction. 99(8). 973–977. 14 indexed citations

19.

Parise, Edison Roberto, Eduardo Luiz Rachid Cançado, Hugo Cheinquer, et al.. (2000). Tratamento da hepatite cronica pelo virus C. 19(5). 203–207. 1 indexed citations

20.

Liang, T. Jake, Lennox J. Jeffers, K. Rajender Reddy, et al.. (1993). Fulminant or subfulminant non-A, non-B viral hepatitis: The role of hepatitis C and E viruses. Gastroenterology. 104(2). 556–562. 110 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact